Yes Biotechnology is developing healthcare solutions to combat disease and reduce the use and misuse of antibiotics.

childYes Biotechnology centers around novel technologies and innovative approaches that will translate into:

  • Point of care diagnostic tools
  • Biomarkers that help target therapy
  • Therapeutic alternatives to antibiotics.

The company’s first product, currently under development, will be announced this year.

Antibiotic Resistance – A Growing Concern

The CDC estimates that at least two million illnesses and 23,000 deaths are caused annually by antibiotic-resistant bacteria in the United States alone.

In 2010, Thomas R. Frieden, Director of the CDC, declared before the U.S. House of Representatives, Subcommittee on Health, that: “…doctors and nurses today are faced with treating infections where antibiotic options are very limited, and in some cases, where no effective antibiotics exist.”



Warned Frieden: “When no antibiotic is effective, healthcare providers may be limited to providing supportive care…similar to how medicine was practiced before antibiotics were discovered.”

To aid in the battle against antibiotic-resistant bacteria, Yes Biotechnology is creating technologies to:

  • Preserve the efficacy of our antibiotic arsenal
  • Combat the emergence of antibiotic-resistant disease.

A National Security Priority

The gravity of antibiotic-resistance was underscored on September 18, 2014, when President Barack Obama issued an Executive Order: Combating Antibiotic-Resistant Bacteria (CARB).

Among its many important calls-to-action, CARB demands immediate efforts to:

  • Preserve the efficacy of new and existing antibacterial drugs
  • Develop improved methods for combating antibiotic resistance and conducting antibiotic stewardship
  • Develop and promote the use of new, rapid diagnostic technologies
  • Accelerate scientific research and facilitate the development of new antibacterial drugs, vaccines, diagnostics, and other novel therapeutics.

Combating antibiotic-resistant bacteria is a national security priority.

— Barack Obama, President of the United States

Positive Outlook

YES Biotechnology views antibiotic resistance as both a problem of global proportions, and an opportunity to move medicine toward novel, specific and powerful techniques for the alleviation of suffering and disease.

Personalized medicine initiatives, for example, are creating diagnostic techniques that will define specific targets of infection at the molecular level, and enable therapies tailored to affect those sites alone.

By avoiding the use of broad spectrum antibiotics, relatively few cells will be exposed to the natural mechanisms that create antibiotic resistance.

Tailored antibiotic therapy may have additional benefits, such as:

  • Extending the clinical lifetime of new antibiotics by better managing resistance
  • Reviving the efficacy of old antibiotics.